查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1995466

節肢動物傳播病毒傳染病檢查市場：依檢測類型、技術、檢體類型、疾病類型及最終用戶分類－2026-2032年全球市場預測

Arthropod-borne Viral Infections Testing Market by Test Type, Technology, Sample Type, Disease Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，節肢動物傳播病毒傳染病檢查市場價值將達到 126.6 億美元，到 2026 年將成長至 137.5 億美元，到 2032 年將達到 228.8 億美元，複合年成長率為 8.82%。

主要市場統計數據
基準年 2025 126.6億美元
預計年份：2026年 137.5億美元
預測年份 2032 228.8億美元
複合年成長率 (%) 8.82%

針對節肢動物傳播病毒感染疾病的威脅，制定了一套全面的診斷優先事項、操作挑戰和協作方法框架。

節肢動物傳播的病毒感染疾病呈現出複雜且不斷變化的診斷格局，其特徵是臨床緊迫性、公共衛生監測以及技術的快速發展。本執行摘要概述了臨床醫生、檢查室管理人員和政策制定者目前面臨的挑戰，因為媒介傳播病原體需要更細緻的診斷應對措施。目前的診斷重點不僅包括快速檢測病原體，還包括區分急性感染和先前感染、在流行地區進行多重識別以及整合監測數據以指導公共衛生干預措施。

技術融合、資料互通性和彈性供應鏈如何改變蟲媒病毒感染疾病的診斷和公共衛生應對措施。

在技​​術創新、流行病學變化以及相關人員日益成長的期望的推動下，節肢動物傳播病毒檢測領域正經歷著一場變革。核酸擴增技術的進步拓展了分子檢測的實際應用範圍，使其不再局限於中心檢查室，從而實現了在患者身邊進行檢測，兼具強大的分析能力和更短的反應時間。同時，免疫檢測分析方法和側向層析檢測設計的改進也提升了抗體和抗原檢測在照護現場和分散式檢測環境中的效用。

對 2025 年關稅措施對診斷藥物採購、供應鏈韌性和生產本地化策略的影響進行系統性評估。

美國自2025年起實施的累積關稅對診斷偵測基礎設施、採購趨勢和供應鏈策略產生了多方面的影響。試劑、檢測盒和儀器組件等關鍵零件進口成本的上升迫使許多診斷服務提供者和實驗室重新評估其籌資策略。為此，一些製造商加快了關鍵生產能力的本地化進程，而另一些製造商則與供應商重新談判合約或修改產品設計，以減少對受關稅影響的原料的依賴。

將測試類型、技術平台、檢體基質、最終用戶需求和病原體特異性診斷途徑連結起來的綜合細分分析。

關鍵的細分洞察闡明瞭如何根據臨床、檢查室和監測目標來客製化檢測策略和技術選擇。在考慮檢測類型時，相關人員需要了解抗體檢測、抗原檢測和分子檢測的互補作用。抗體檢測，包括區分IgG和IgM抗體的檢測方法，可提供有關免疫史和暴露模式的關鍵信息，從而支持血清監測和回顧性病例分類。抗原檢測，包括酵素免疫分析法（ELISA）和快速抗原檢測，在即時臨床分流和照護現場決策方面具有實際優勢。分子檢測，例如常規PCR、等溫擴增和即時PCR，仍然是病原體確診和基因分型的黃金標準，對於急性病例的明確診斷和基於序列的監測至關重要。

區域診斷需求和基礎設施現狀決定了世界各地不同的技術部署、監測重點和區域特定實施方法。

區域情況會影響診斷策略的優先排序和實施。在美洲，公共衛生機構和檢查室網路正努力應對都市區地區不同的流行病學壓力，因此需要靈活的診斷方法，將快速篩檢與密集的確認檢測相結合。這種需求源自於應對集體爆發的準備工作、跨境監測以及維持對其他蟲媒病毒的檢測能力。因此，投資越來越集中於那些既能支持綜合報告系統，又能擴展並適應病例數波動的平台。

診斷公司之間的競爭和策略舉措：重點關注產品組合廣度、夥伴關係關係、監管合應對力和供應鏈敏捷性。

節肢動物傳播病毒檢測領域的企業層面趨勢揭示了影響競爭定位和創新路徑的幾個通用主題。在該領域，各公司都在投資於包含快速抗原檢測、高通量免疫檢測和分子診斷平台的一體化產品系列，以滿足臨床和監測環境中的各種應用需求。策略夥伴關係和共同開發契約正逐漸成為加速檢測檢驗、拓展通路和整合互補技術能力的常用手段。

為領導企業提供可操作的策略步驟和營運重點，以增強產品系列、供應鏈、監管參與和數據整合。

我們為產業領導者提供的切實可行的建議強調，技術選擇應與營運實際情況和策略韌性相契合。優先考慮均衡的產品組合策略，整合快速抗原檢測解決方案、強大的免疫檢測平台和便利的分子診斷技術，以滿足緊急臨床需求、血清監測目標和確證檢測要求。除了產品多元化之外，還應輔以服務導向型能力，例如培訓、能力驗證計劃和遠端技術支持，以加快部署速度並在所有用戶環境中保持高品質的效能。

研究結果的有效性透過穩健的混合方法檢驗，該方法結合了專家訪談、二手技術文獻整合和多階段品質保證。

本報告的調查方法結合了基於三角測量的證據收集、專家諮詢和嚴格的品管，以確保分析的可靠性。主要研究包括對臨床實驗室負責人、分子診斷和免疫檢測專家、公共衛生從業人員以及採購負責人進行結構化訪談，從而獲得關於不同環境下的操作限制、技術偏好和應用障礙的第一手觀點。次要研究則利用同儕審查文獻、監管指導文件、技術白皮書和公開的監測資料集，為主要研究結果提供背景資訊並檢驗技術論點。

整合策略挑戰，強調技術整合、系統性韌性和數據驅動的協作方法，以建立永續的診斷系統。

總之，針對節肢動物傳播病毒感染疾病的診斷應對正處於一個轉折點，其特點是技術能力的加速發展、對供應鏈韌性的日益重視以及對數據驅動型監測的期望不斷提高。有效的策略依賴抗體、抗原和分子檢測等互補檢測方法的整合，同時也要選擇能夠適應不同終端使用者和檢體情況的技術。政策制定者和採購經理必須優先考慮靈活的生產製造和可靠的供應鏈，在快速獲得診斷結果與系統的長期永續性之間取得平衡。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 節肢動物傳播病毒傳染病檢查：檢測類型

  • 抗體檢測
    • IgG抗體
    • IgM抗體
  • 抗原檢測
    • ELISA抗原
    • 快速抗原檢測
  • 分子檢測
    • 常規PCR
    • 等溫擴增
    • 即時PCR

第9章：節肢動物傳播病毒傳染病檢查市場：依技術分類

  • 免疫檢測
    • 化學冷光免疫檢測
    • ELISA
    • 側向流動免疫檢測
  • 次世代定序
    • Illumina定序
    • 焦磷酸測序
  • 基於PCR的技術
    • 常規PCR
    • 等溫擴增
    • 即時PCR
  • 快速診斷測試
    • 橫向流動化驗
    • 光學免疫檢測

第10章 節肢動物傳播病毒傳染病檢查：檢體類型

  • 血清
  • 腦脊髓液
  • 電漿
  • 唾液
  • 全血

第11章：節肢動物傳播病毒傳染病檢查市場：依疾病類型分類

  • 基孔古尼亞
  • 登革熱
  • 西尼羅河
  • 黃熱病
  • 茲卡

第12章：節肢動物傳播傳染病檢查市場：依最終用戶分類

  • 學術機構
  • 診斷中心
  • 醫院檢查室
  • 參考檢測實驗室
  • 研究機構

第13章：節肢動物傳播傳染病檢查市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：節肢動物傳播傳染病檢查市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：節肢動物傳播病毒傳染病檢查市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國節肢動物傳播病毒傳染病檢查市場

第17章：中國節肢動物傳播病毒傳染病檢查市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Abnova Corporation
  • AdvaCare Pharma
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Chembio Diagnostics, Inc.
  • DiaSorin SpA
  • EUROIMMUN AG by PerkinElmer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-4103B31E09C0

The Arthropod-borne Viral Infections Testing Market was valued at USD 12.66 billion in 2025 and is projected to grow to USD 13.75 billion in 2026, with a CAGR of 8.82%, reaching USD 22.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 12.66 billion
Estimated Year [2026] USD 13.75 billion
Forecast Year [2032] USD 22.88 billion
CAGR (%) 8.82%

Comprehensive framing of diagnostic priorities, operational imperatives, and collaborative approaches to address arthropod-borne viral threats

Arthropod-borne viral infections present a complex and evolving diagnostic landscape that intersects clinical urgency, public health surveillance, and rapid technological advancement. The introduction to this executive summary frames the contemporary challenges faced by clinicians, laboratory leaders, and policymakers as vector-borne pathogens continue to demand nuanced diagnostic responses. Diagnostic priorities now include not only timely pathogen detection but also differentiation between acute and past infections, multiplexed identification in co-endemic settings, and integration of surveillance data to guide public health interventions.

Across clinical environments, diagnostic workflows are being rebalanced to achieve higher sensitivity and specificity while preserving speed and cost-effectiveness. Laboratories must weigh the trade-offs among antibody assays that provide serostatus context, antigen tests that offer rapid point-of-care functionality, and molecular modalities that deliver definitive pathogen identification. Concurrently, surveillance systems require standardized data streams from diverse end users such as hospital laboratories, reference centers, and academic institutions to construct actionable epidemiologic intelligence.

This introduction underscores the need for cohesive strategies that align diagnostic innovation with operational realities, regulatory requirements, and supply chain considerations. It establishes the premise that effective responses to arthropod-borne viruses will depend on strategic deployment of tests across settings, careful selection of technologies appropriate to clinical questions, and continuous collaboration between public health authorities and diagnostic developers.

How technological convergence, data interoperability, and resilient supply chains are reshaping diagnostics and public health responses to arboviral disease

The landscape for arthropod-borne viral testing is undergoing transformative shifts driven by technological innovation, changing epidemiology, and evolving stakeholder expectations. Advances in nucleic acid amplification methods have expanded the practicality of molecular testing beyond centralized laboratories, enabling near-patient platforms that combine shortened time-to-result with robust analytical performance. At the same time, improvements in immunoassay formats and lateral flow designs have enhanced the utility of antibody and antigen testing in both point-of-care and decentralized settings.

Beyond assay innovation, data integration is altering diagnostic value propositions. Real-time data streams and interoperable reporting systems strengthen surveillance capabilities and accelerate outbreak detection. This trend is complemented by an increased emphasis on multiplexing and syndromic panels that can resolve coinfections and overlapping clinical presentations common in regions with multiple circulating arboviruses. Regulatory authorities are also refining pathways to support rapid deployment of validated tests during emergent situations while maintaining quality and safety standards.

Supply chain resilience and manufacturing agility have become central to strategic planning. Diagnostic developers are investing in diversified sourcing and modular production approaches to mitigate disruptions. Collectively, these shifts reflect a move toward more adaptive, networked diagnostic ecosystems where technological performance, data connectivity, regulatory alignment, and supply chain robustness converge to reshape how arthropod-borne viral infections are detected and managed.

Assessing the systemic consequences of 2025 tariff measures on diagnostics procurement, supply chain resilience, and manufacturing localization strategies

The introduction of cumulative tariffs by the United States in 2025 has exerted multifaceted effects across diagnostic testing infrastructure, procurement dynamics, and supply chain strategies. Rising import costs for key components such as reagents, assay cartridges, and instrument subassemblies have compelled many diagnostic providers and laboratories to reassess sourcing strategies. In response, some manufacturers accelerated localization of critical production capacity, while others renegotiated supplier contracts or adapted product designs to reduce reliance on tariff-impacted inputs.

These adjustments have translated into operational changes across the diagnostic ecosystem. Clinical laboratories and reference facilities re-evaluated procurement cycles, prioritizing long-term supplier partnerships and inventory management practices that buffer short-term price volatility. Public health programs assessing procurement for outbreak preparedness emphasized supplier diversity and contingency planning. At the same time, government procurement agencies and regulatory bodies engaged in dialogue to balance trade policy objectives with public health imperatives, encouraging exemptions or temporary relief for life-critical medical goods in certain circumstances.

The tariff environment also influenced strategic decision-making for diagnostic companies considering investments in manufacturing footprint and supply chain redundancy. Some organizations accelerated investment in domestic or near-shore production to ensure continuity for high-priority assay components, while others pursued collaborative manufacturing agreements to distribute risk. Ultimately, the cumulative impact of trade policy shifts in 2025 reinforced the strategic importance of supply chain visibility, flexible manufacturing, and procurement governance in safeguarding diagnostic readiness for arthropod-borne viral threats.

Integrated segmentation analysis linking test types, technology platforms, specimen matrices, end-user requirements, and pathogen-specific diagnostic pathways

Key segmentation insights illuminate how testing strategies and technology choices must be tailored to clinical, laboratory, and surveillance objectives. When considering test type, stakeholders must navigate the complementary roles of antibody testing, antigen testing, and molecular testing. Antibody testing, including assays that differentiate IgG from IgM antibodies, offers critical information about immune history and exposure patterns, which supports serosurveillance and retrospective case classification. Antigen testing, encompassing enzyme-linked immunosorbent (ELISA) antigen formats and rapid antigen approaches, delivers practical benefits for immediate clinical triage and point-of-care decision-making. Molecular testing modalities such as conventional PCR, isothermal amplification, and real-time PCR remain the gold standard for definitive pathogen detection and genotyping, and are pivotal for acute case confirmation and sequence-based surveillance.

Technology choices further refine diagnostic performance and operational fit. Immunoassay platforms-ranging from chemiluminescent immunoassays to ELISA and lateral flow immunoassays-provide scale, throughput, and diverse deployment options. Next generation sequencing technologies, including Illumina sequencing and pyrosequencing, enable in-depth pathogen characterization and genomic surveillance, particularly valuable for tracking viral evolution and transmission pathways. PCR-based technologies span conventional and real-time PCR as well as isothermal amplification techniques that facilitate decentralized molecular diagnostics. Rapid diagnostic tests, represented by lateral flow assays and optical immunoassays, deliver speed and ease-of-use for frontline settings.

End user segmentation shapes procurement and implementation strategies. Academic institutions and research institutes prioritize platforms that support method development and genomic studies, whereas hospital laboratories and diagnostic centers emphasize throughput, turnaround time, and integration with clinical workflows. Reference laboratories play a central role in confirmatory testing and quality assurance, supplying standardized testing and specialized services to regional networks. Sample type considerations-blood serum, cerebrospinal fluid, plasma, saliva, and whole blood-determine specimen handling protocols, assay sensitivity, and clinical utility, with specific sample matrices favored for different disease presentations. Finally, disease type segmentation across chikungunya, dengue, West Nile, yellow fever, and Zika dictates diagnostic algorithms; some pathogens necessitate molecular confirmation during the acute phase while others rely heavily on serologic interpretation for later-stage diagnosis and surveillance.

Understanding these layered segmentation dynamics enables decision-makers to align diagnostic offerings to clinical needs, surveillance goals, and operational capabilities while recognizing the interoperability and complementarity among test types, technologies, end users, sample types, and disease targets.

Regional diagnostic imperatives and infrastructure realities shaping technology adoption, surveillance priorities, and localized implementation approaches across global regions

Regional dynamics affect how diagnostic strategies are prioritized and operationalized. In the Americas, public health agencies and laboratory networks contend with diverse epidemiologic pressures across urban and rural contexts, necessitating flexible diagnostics that combine rapid screening with centralized confirmatory testing. Demand drivers include outbreak response readiness, cross-border surveillance, and the need to maintain laboratory capacity for co-circulating arboviruses. Consequently, investments often emphasize platforms that can scale and adapt to shifting caseloads while supporting integrated reporting systems.

Across Europe, the Middle East & Africa, heterogeneous healthcare systems and resource environments create differentiated adoption patterns. High-capacity laboratories in urban centers and reference networks tend to leverage advanced molecular and sequencing technologies for precise pathogen characterization, whereas decentralized settings prioritize cost-effective rapid diagnostics and robust quality assurance programs. Surveillance priorities in this region frequently focus on strengthening sample referral pathways and harmonizing diagnostic algorithms to support timely outbreak detection and cross-jurisdictional collaboration.

In the Asia-Pacific region, the combination of endemic arboviral transmission in certain geographies and rapidly evolving laboratory capabilities drives both high demand for multiplexed diagnostics and active investment in point-of-care solutions. Countries with established industrial bases and manufacturing capabilities pursue domestic production and technology transfer to support self-reliance, while others focus on building laboratory networks and enhancing training to expand molecular testing capacity. Across regions, the interplay between infrastructure, regulatory environments, and epidemiology shapes which technologies and implementation models are most viable.

Competitive dynamics and strategic maneuvers among diagnostic firms focusing on portfolio breadth, partnerships, regulatory readiness, and supply chain agility

Company-level dynamics in the arthropod-borne viral testing space reveal several converging themes that influence competitive positioning and innovation trajectories. Across the sector, firms are investing in integrated product portfolios that span rapid antigen assays, high-throughput immunoassays, and molecular platforms to address diverse use cases across clinical and surveillance settings. Strategic partnerships and cooperative development agreements have become common pathways to accelerate assay validation, expand distribution channels, and combine complementary technical capabilities.

Manufacturers are increasingly focused on quality systems, regulatory preparedness, and post-market surveillance to ensure sustained clinical utility and trust among laboratory customers. There is a notable emphasis on formalizing customer support infrastructures, including training, proficiency testing, and remote diagnostics to reduce downtime and optimize assay performance in varied settings. In addition, firms with capabilities in sequencing and bioinformatics are expanding offerings that link diagnostic outputs to actionable epidemiologic intelligence, thereby enhancing the value proposition for public health clients and large diagnostic networks.

Supply chain optimization and manufacturing agility remain competitive differentiators. Organizations that have established diversified supplier bases, near-shore production options, and flexible contract manufacturing relationships are better positioned to navigate procurement disruptions and policy shifts. Finally, investment in data interoperability, cloud-enabled reporting, and cybersecurity measures is becoming a standard expectation as diagnostics increasingly feed into broader health information ecosystems.

Practical strategic steps and operational priorities for diagnostic leaders to strengthen portfolios, supply chains, regulatory engagement, and data integration

Actionable recommendations for industry leaders emphasize aligning technological choices with operational realities and strategic resilience. Prioritize a balanced portfolio strategy that integrates rapid antigen solutions, robust immunoassay platforms, and accessible molecular diagnostics to cover acute clinical needs, serosurveillance objectives, and confirmatory testing requirements. Complement product diversification with service-oriented capabilities such as training, proficiency programs, and remote technical support to enhance adoption and sustain quality performance across user settings.

Invest in supply chain transparency and manufacturing flexibility to mitigate policy-driven cost pressures and logistical disruptions. Consider near-shore or redundant production arrangements for critical reagents and components, and cultivate strategic supplier partnerships to preserve continuity. Strengthen data interoperability by adopting standardized reporting formats and secure data transmission protocols so diagnostic outputs can effectively inform public health surveillance and clinical decision support systems.

Engage proactively with regulatory authorities to streamline validation pathways for emergent diagnostics and to secure conditional access during outbreak scenarios. Expand collaborative initiatives with public health laboratories, academic institutions, and reference networks to validate assays across diverse specimen types and disease contexts. Finally, embed a continuous learning cycle that captures real-world performance data and stakeholder feedback to guide iterative product improvements and service enhancements.

Robust mixed-methods approach combining primary expert interviews, secondary technical literature synthesis, and multi-stage quality assurance to validate insights

The research methodology underpinning this report combines triangulated evidence gathering, expert consultation, and rigorous quality controls to ensure analytic robustness. Primary research included structured interviews with clinical laboratory directors, molecular and immunoassay subject-matter experts, public health practitioners, and procurement professionals, enabling firsthand perspectives on operational constraints, technology preferences, and implementation barriers across settings. Secondary research sources comprised peer-reviewed literature, regulatory guidance documents, technical white papers, and publicly available surveillance datasets to contextualize primary insights and validate technical assertions.

Analytic processes applied systematic framework mapping to reconcile divergent data streams, followed by qualitative synthesis to surface thematic priorities such as assay selection criteria, specimen handling considerations, and supply chain vulnerabilities. Quality assurance measures included cross-validation of interview findings with documented performance characteristics, iterative review by independent experts, and consistency checks to ensure terminological precision and methodological transparency. Limitations are acknowledged, including variability in regional reporting practices and evolving policy environments that may affect implementation outcomes. Wherever possible, findings were framed to highlight relative priorities and operational implications rather than absolute measures, supporting actionable decision-making by laboratory leaders and health program managers.

Synthesis of strategic imperatives underscoring technology integration, system resilience, and collaborative data-driven approaches for sustained diagnostic readiness

In conclusion, the diagnostic response to arthropod-borne viral infections is at an inflection point, characterized by accelerating technological capability, heightened emphasis on supply chain resilience, and intensifying expectations for data-driven surveillance. Effective strategies will hinge on integrating complementary test types-antibody, antigen, and molecular-while matching technology selection to the needs of diverse end users and specimen contexts. Policymakers and procurement leaders must balance rapid access to diagnostics with long-term system sustainability, prioritizing flexible manufacturing and secure supply arrangements.

Stakeholders should also embrace interoperability and data integration as central pillars of modern diagnostic ecosystems, enabling rapid translation of laboratory findings into public health action. By investing in training, quality systems, and collaborative validation efforts, the sector can improve diagnostic reliability and readiness for future arboviral challenges. Looking forward, adaptive strategies that combine technological innovation, operational rigor, and cross-sector collaboration will be essential to deliver timely, accurate, and actionable diagnostic information where and when it matters most.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Arthropod-borne Viral Infections Testing Market, by Test Type

  • 8.1. Antibody Testing
    • 8.1.1. IgG Antibody
    • 8.1.2. IgM Antibody
  • 8.2. Antigen Testing
    • 8.2.1. Elisa Antigen
    • 8.2.2. Rapid Antigen
  • 8.3. Molecular Testing
    • 8.3.1. Conventional PCR
    • 8.3.2. Isothermal Amplification
    • 8.3.3. Real Time PCR

9. Arthropod-borne Viral Infections Testing Market, by Technology

  • 9.1. Immunoassay
    • 9.1.1. Chemiluminescent Immunoassay
    • 9.1.2. Elisa
    • 9.1.3. Lateral Flow Immunoassay
  • 9.2. Next Generation Sequencing
    • 9.2.1. Illumina Sequencing
    • 9.2.2. Pyrosequencing
  • 9.3. PCR Based Technologies
    • 9.3.1. Conventional PCR
    • 9.3.2. Isothermal Amplification
    • 9.3.3. Real Time PCR
  • 9.4. Rapid Diagnostic Test
    • 9.4.1. Lateral Flow Assay
    • 9.4.2. Optical Immunoassay

10. Arthropod-borne Viral Infections Testing Market, by Sample Type

  • 10.1. Blood Serum
  • 10.2. Cerebrospinal Fluid
  • 10.3. Plasma
  • 10.4. Saliva
  • 10.5. Whole Blood

11. Arthropod-borne Viral Infections Testing Market, by Disease Type

  • 11.1. Chikungunya
  • 11.2. Dengue
  • 11.3. West Nile
  • 11.4. Yellow Fever
  • 11.5. Zika

12. Arthropod-borne Viral Infections Testing Market, by End User

  • 12.1. Academic Institutions
  • 12.2. Diagnostic Centers
  • 12.3. Hospital Laboratories
  • 12.4. Reference Laboratories
  • 12.5. Research Institutes

13. Arthropod-borne Viral Infections Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Arthropod-borne Viral Infections Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Arthropod-borne Viral Infections Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Arthropod-borne Viral Infections Testing Market

17. China Arthropod-borne Viral Infections Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Abnova Corporation
  • 18.7. AdvaCare Pharma
  • 18.8. Bio-Rad Laboratories, Inc.
  • 18.9. bioMerieux SA
  • 18.10. Chembio Diagnostics, Inc.
  • 18.11. DiaSorin S.p.A.
  • 18.12. EUROIMMUN AG by PerkinElmer Inc.
  • 18.13. F. Hoffmann-La Roche Ltd.
  • 18.14. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGG ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGG ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGG ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGM ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGM ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGM ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA ANTIGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA ANTIGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA ANTIGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID ANTIGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID ANTIGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID ANTIGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PYROSEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PYROSEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PYROSEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY OPTICAL IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY OPTICAL IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY OPTICAL IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY BLOOD SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY BLOOD SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY BLOOD SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CEREBROSPINAL FLUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CEREBROSPINAL FLUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHIKUNGUNYA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHIKUNGUNYA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHIKUNGUNYA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DENGUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DENGUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DENGUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WEST NILE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WEST NILE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WEST NILE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY YELLOW FEVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY YELLOW FEVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY YELLOW FEVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ZIKA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ZIKA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ZIKA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
  • TABLE 253. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
  • TABLE 254. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
  • TABLE 255. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 257. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 258. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 259. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 260. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARK